...
exas-img

EXACT Sciences Corporation, Common Stock

EXAS

NAQ

$58.79

-$4.45

(-7.04%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$10.67B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
NM
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.65M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
3.19M
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.23
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$56.05 L
$100.77 H
$58.79

About EXACT Sciences Corporation, Common Stock

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameEXASSectorS&P500
1-Week Return-7.39%1.76%1.21%
1-Month Return-7.79%-3.02%-2.81%
3-Month Return-8.51%2.09%3.9%
6-Month Return-4.89%12.25%21.95%
1-Year Return-7.49%7.16%26.39%
3-Year Return-57.79%19.75%26.72%
5-Year Return-38.37%74.24%88.05%
10-Year Return365.48%188.4%226.82%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue876.29M1.49B1.77B2.08B2.50B[{"date":"2019-12-31","value":35.06,"profit":true},{"date":"2020-12-31","value":59.66,"profit":true},{"date":"2021-12-31","value":70.69,"profit":true},{"date":"2022-12-31","value":83.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue216.72M354.32M458.76M574.39M654.20M[{"date":"2019-12-31","value":33.13,"profit":true},{"date":"2020-12-31","value":54.16,"profit":true},{"date":"2021-12-31","value":70.12,"profit":true},{"date":"2022-12-31","value":87.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit659.58M1.14B1.31B1.51B1.85B[{"date":"2019-12-31","value":35.74,"profit":true},{"date":"2020-12-31","value":61.61,"profit":true},{"date":"2021-12-31","value":70.89,"profit":true},{"date":"2022-12-31","value":81.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin75.27%76.24%74.04%72.44%73.83%[{"date":"2019-12-31","value":98.72,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.11,"profit":true},{"date":"2022-12-31","value":95.02,"profit":true},{"date":"2023-12-31","value":96.84,"profit":true}]
Operating Expenses893.36M1.70B2.14B2.09B2.06B[{"date":"2019-12-31","value":41.67,"profit":true},{"date":"2020-12-31","value":79.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.37,"profit":true},{"date":"2023-12-31","value":96.09,"profit":true}]
Operating Income(233.78M)(558.35M)(835.47M)(577.54M)(215.01M)[{"date":"2019-12-31","value":-23378200000,"profit":false},{"date":"2020-12-31","value":-55835300000,"profit":false},{"date":"2021-12-31","value":-83546800000,"profit":false},{"date":"2022-12-31","value":-57754200000,"profit":false},{"date":"2023-12-31","value":-21501200000,"profit":false}]
Total Non-Operating Income/Expense(96.67M)(386.78M)(25.64M)(74.66M)12.64M[{"date":"2019-12-31","value":-764.48,"profit":false},{"date":"2020-12-31","value":-3058.77,"profit":false},{"date":"2021-12-31","value":-202.8,"profit":false},{"date":"2022-12-31","value":-590.45,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(268.85M)(857.11M)(842.51M)(632.57M)(201.75M)[{"date":"2019-12-31","value":-26885100000,"profit":false},{"date":"2020-12-31","value":-85710500000,"profit":false},{"date":"2021-12-31","value":-84250600000,"profit":false},{"date":"2022-12-31","value":-63257000000,"profit":false},{"date":"2023-12-31","value":-20174600000,"profit":false}]
Income Taxes(184.86M)(8.57M)(246.88M)(9.06M)2.40M[{"date":"2019-12-31","value":-7692.8,"profit":false},{"date":"2020-12-31","value":-356.72,"profit":false},{"date":"2021-12-31","value":-10273.87,"profit":false},{"date":"2022-12-31","value":-377.2,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(83.99M)(848.53M)(595.63M)(623.51M)(204.15M)[{"date":"2019-12-31","value":-8399300000,"profit":false},{"date":"2020-12-31","value":-84853300000,"profit":false},{"date":"2021-12-31","value":-59562500000,"profit":false},{"date":"2022-12-31","value":-62350600000,"profit":false},{"date":"2023-12-31","value":-20414900000,"profit":false}]
Income From Continuous Operations(83.99M)(848.53M)(595.63M)(623.51M)(204.15M)[{"date":"2019-12-31","value":-8399300000,"profit":false},{"date":"2020-12-31","value":-84853300000,"profit":false},{"date":"2021-12-31","value":-59562500000,"profit":false},{"date":"2022-12-31","value":-62350600000,"profit":false},{"date":"2023-12-31","value":-20414900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(83.99M)(848.53M)(595.63M)(623.51M)(204.15M)[{"date":"2019-12-31","value":-8399300000,"profit":false},{"date":"2020-12-31","value":-84853300000,"profit":false},{"date":"2021-12-31","value":-59562500000,"profit":false},{"date":"2022-12-31","value":-62350600000,"profit":false},{"date":"2023-12-31","value":-20414900000,"profit":false}]
EPS (Diluted)(0.65)(4.30)(3.46)(3.43)(1.14)[{"date":"2019-12-31","value":-65,"profit":false},{"date":"2020-12-31","value":-430,"profit":false},{"date":"2021-12-31","value":-346,"profit":false},{"date":"2022-12-31","value":-343,"profit":false},{"date":"2023-12-31","value":-113.57,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

EXAS
Cash Ratio 1.51
Current Ratio 2.32
Quick Ratio 2.07

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

EXAS
ROA (LTM) -3.04%
ROE (LTM) -6.60%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

EXAS
Debt Ratio Lower is generally better. Negative is bad. 0.51
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.49
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 2.06

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

EXAS
Trailing PE NM
Forward PE NM
P/S (TTM) 5.18
P/B 4.12
Price/FCF 332
EV/R 5.89
EV/Ebitda 503.12
PEG NM

News

Exact Sciences Announces Board Member Retirement

Exact Sciences Corp. (EXAS) just unveiled an update. Dr. Freda Lewis-Hall, a board member of Exact Sciences Corporation, plans to retire immediatel…

25 Apr, 2024 a 8:45 pm TipRanks

Here’s Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS)

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]

24 Apr, 2024 a 11:16 am Insider Monkey

Exact Sciences names Aaron Bloomer as new CFO By Investing.com

MADISON, Wis. – Exact Sciences Corp. (NASDAQ:), known for its cancer screening and diagnostic tests, has announced the appointment of Aaron Bloomer as its new Chief Financial Officer, with his term set to begin on May 15, 2024. Bloomer will initially join the company as Executive Vice President of Finance and will transition into the […] The post Exact Sciences names Aaron Bloomer as new CFO By Investing.com appeared first on TheAdviserMagazine.com .

15 Apr, 2024 a 10:41 am TheAdviserMagazine.com

Exact Sciences Appoints Aaron Bloomer as New CFO

Exact Sciences Corp. (EXAS) has shared an update. Exact Sciences Corporation has announced the appointment of Aaron Bloomer as their new CFO, effec…

15 Apr, 2024 a 10:32 am TipRanks

Exact Sciences Names Aaron Bloomer as New Chief Financial Officer

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previously held leadership positions at Baxter International and 3M, where he helped improve financial Jetzt den vollständigen Artikel lesen

15 Apr, 2024 a 10:00 am Wallstreet:Online

Exact Sciences Names Aaron Bloomer as New Chief Financial Officer | EXAS Stock News

Exact Sciences appoints Aaron Bloomer as new Chief Financial Officer, bringing over 15 years of finance and accounting experience from companies like Baxter International and 3M. Bloomer''s global expertise in setting corporate strategy and driving growth will aid Exact Sciences in expanding its cancer screening and diagnostic tests portfolio.

15 Apr, 2024 a 10:00 am Stock Titan

Here’s Why Exact Sciences Corporation (EXAS) Declined in Q1

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, the fund’s Investor Class fund ARTMX returned 10.41%, Advisor Class fund APDMX posted a return of 10.40%, and Institutional Class fund APHMX returned 10.44%, compared […]

12 Apr, 2024 a 11:00 am Insider Monkey

FAQs

What is EXACT Sciences Corporation share price today?

EXACT Sciences Corporation (EXAS) share price today is $58.79

Can Indians buy EXACT Sciences Corporation shares?

Yes, Indians can buy shares of EXACT Sciences Corporation (EXAS) on Vested. To buy EXACT Sciences Corporation from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EXAS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of EXACT Sciences Corporation be purchased?

Yes, you can purchase fractional shares of EXACT Sciences Corporation (EXAS) via the Vested app. You can start investing in EXACT Sciences Corporation (EXAS) with a minimum investment of $1.

How to invest in EXACT Sciences Corporation shares from India?

You can invest in shares of EXACT Sciences Corporation (EXAS) via Vested in three simple steps:

  • Click on Sign Up or Invest in EXAS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in EXACT Sciences Corporation shares
What is EXACT Sciences Corporation 52-week high and low stock price?

The 52-week high price of EXACT Sciences Corporation (EXAS) is $100.77. The 52-week low price of EXACT Sciences Corporation (EXAS) is $56.05.

What is EXACT Sciences Corporation price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of EXACT Sciences Corporation (EXAS) is NM

What is EXACT Sciences Corporation price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of EXACT Sciences Corporation (EXAS) is 4.12

What is EXACT Sciences Corporation dividend yield?

The dividend yield of EXACT Sciences Corporation (EXAS) is 0.00%

What is the Market Cap of EXACT Sciences Corporation?

The market capitalization of EXACT Sciences Corporation (EXAS) is $10.67B

What is EXACT Sciences Corporation’s stock symbol?

The stock symbol (or ticker) of EXACT Sciences Corporation is EXAS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top